Publications by authors named "S P De Filippis"
Partial Dopamine D2/3 Agonists and Dual Disorders: A Retrospective-Cohort Study in a Real-World Clinical Setting on Patients with Schizophrenia Spectrum Disorders and Cannabis Use Disorder.
Curr Neuropharmacol
January 2025
Introduction/objective: Schizophrenia with substance use disorder is a complex clinical condition that may increase treatment resistance. Cannabis use disorder is frequently associated with psychosis and the causal link has still to be defined. Partial D2/3 agonists may ensure limbic dopamine release normalization while avoiding reduced frontocortical dopamine release, which would contribute to negative symptoms.
View Article and Find Full Text PDFArticle Synopsis
- * PMA occurs in 4.3% to 10% of psychiatric emergencies, creating a heavy burden on healthcare systems, yet there’s a gap in standardized treatment protocols, especially regarding the use of liquid antipsychotics like liquid promazine.
- * The review analyzes the benefits of liquid promazine, which include ease of use, quick action, and better patient adherence, but emphasizes the need for further research to validate its effectiveness compared to other antips
Long coronavirus disease (COVID), also known as the post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC), is a significant concern since the end of the COVID-19 pandemic, as it still manifests in individuals with persistent symptoms and complications beyond the acute phase of infection. Defining this disease is challenging, as it manifests as a spectrum of symptoms varying in severity among individuals who have previously tested positive for COVID-19. Long COVID is more prevalent in hospitalized COVID-19 patients and presents in various ways, ranging from pulmonary to extrapulmonary symptoms.
View Article and Find Full Text PDFBackground: Although second-generation antipsychotics (SGAs) have proven to be effective therapeutic options for patients with schizophrenia, there is a notable lack of evidence on patients' subjective perspectives regarding their well-being, quality of life, and satisfaction with these medications. This study aimed to evaluate the treatment satisfaction and effectiveness of lurasidone on quality of life and functioning in adult patients with schizophrenia in real-world Italian clinical practice.
Methods: This was a multicentre, national, non-interventional, single-arm, 3-month prospective study.
Article Synopsis
- Treatment-Resistant Depression (TRD) affects about 30% of people with Major Depressive Disorder, and a new nasal spray called Esketamine (ESK-NS) has been approved to help treat it when combined with certain medications.
- Researchers wanted to see if combining Vortioxetine, another antidepressant, with ESK-NS was just as good or better than the usual treatment.
- The results showed that the Vortioxetine and ESK-NS combo worked well to reduce depression and had fewer side effects, suggesting it could be a better option, but more research is needed to be sure.